The text starts here.

Clinical Trial Summary Result

Eisai is committed to enhancing patient health through transparency in its clinical research and the responsible sharing of clinical trial data in a manner in keeping with our hhc mission.

The clinical trial result summaries contained on this website are from clinical trials sponsored by Eisai and are provided for informational purposes only. These summaries contain data from the specific study population but do not include the patient-level data from each study participant. The results reported in any single trial may not reflect the overall potential risks or benefits associated with Eisai's products.

Only health care professionals may determine if a specific product is appropriate as a treatment option for a particular patient. Health care professionals should refer to the specific labeling information approved in their country when making prescribing decisions.

The information provided is not intended to commercialize or promote Eisai's products for any unapproved uses.

All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information contained on this website. Eisai reserves the right to amend any information on this website at any time at its sole discretion.

CSR synopses
Search Search Help

Generic Name
Study ID
Study title
(Clinicaltrials.gov identifier)
Lenvatinib
Phase 2, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology (NCT00784303)
Lenvatinib
A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer (NCT01728623)
Lenvatinib
The SELECT Trial ; A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (NCT01321554)